PEI-DNA Complex Stabilization for Scalable Viral Vector Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing viral vectors, such as lentiviral and adeno-associated virus vectors, face challenges in scaling up production while maintaining culture productivity and efficiency, particularly due to the sensitivity of PEI/DNA complex hold time and the need for animal-derived products like fetal bovine serum, which can introduce contamination and increase costs.
Innovation Solution
The development of methods and systems for stabilizing PEI-DNA complexes by controlling the concentration and mixing time of PEI and DNA solutions, using stabilizing agents like human serum albumin, and optimizing the size of polymer-DNA nanoparticles to enhance transfection efficacy and viral vector production, allowing for serum-free suspension processes and scalable production without animal-derived materials.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If adherent cell cultures are used for viral vector production, then commercial demand can be met, but scale out requirements limit maximum process scale and increase contamination risks
Solution Approach 1:
The patent extracts the limitation of adherent cell culture by transitioning to suspension cell culture, which eliminates the need for scale out and allows for simplified single-vessel scaling while maintaining high productivity
Solution Approach 2:
The patent changes the physical state parameter of cell culture from adherent (attached to surface) to suspension (floating in medium), enabling scalable production without the complexity of scale out operations
2Reliability
If animal-derived serum is added to maintain cell health, then cell viability is maintained, but contamination risk and commercialization costs increase
Solution Approach 1:
The patent removes animal-derived serum from the cell culture medium, eliminating the source of adventitious agent contamination while maintaining cell health through alternative serum-free formulations
Solution Approach 2:
The patent replaces expensive, contamination-prone animal serum with cost-effective, defined serum-free media components that eliminate contamination risks while maintaining cell viability
3Productivity
If PEI/DNA complex hold time is extended, then transfection efficiency may improve, but complex size increases and transfection efficacy decreases
Solution Approach 1:
The patent performs preliminary optimization of the PEI/DNA complexation process by defining precise hold time parameters (30 seconds to 15 minutes) before transfection, ensuring optimal complex size and transfection efficacy are achieved within this controlled timeframe
Solution Approach 2:
The patent implements feedback control by monitoring complex size and adjusting hold time accordingly, using the established relationship between hold time and complex size to optimize transfection outcomes
4Speed
If PEI and DNA concentrations are increased, then complex formation speed increases, but complex size becomes uncontrolled and transfection efficacy decreases
Solution Approach 1:
The patent optimizes the concentration parameters of PEI and DNA solutions to achieve the desired balance between complex formation speed and complex size control, ensuring transfection efficacy is maintained
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach improves viral vector titer and production efficiency, reduces contamination risks, and lowers commercialization costs by enabling scalable, serum-free production processes that maintain high transfection efficacy and viral vector yields.
Implementation Method 1
adding a first predetermined amount of a PEI solution at a first concentration to a second predetermined amount of a DNA solution at a second concentration and mixing to obtain a PEI-DNA complex in solution
Implementation Method 2
polyethyleneimine (PEI)—deoxyribonucleic acid (DNA) complex
Implementation Method 3
adding a third predetermined amount of a PEI-DNA transfection complex stabilizing agent to the PEI-DNA solution to obtain a stabilized PEI-DNA complex
Data Source
AI summary
Disclosed are methods and systems for producing polymer-DNA nanoparticles of a predetermined size. In one example, a method includes mixing together a first solution comprising deoxyribonucleic acid (DNA) with a second solution comprising a cationic polymer to obtain a polyplex solution, and at a predetermined time subsequent to mixing together the first solution and the second solution, adding a polyplex stabilizing agent to stabilize the size of the polyplex. In this way, transfection efficacy of the polymer-DNA nanoparticles may be improved, in particular with reference to transfection of suspension cells for production of viral vectors.